Global Cancer Biomarker Market - 2026-2032
Global Cancer Biomarker Market reached USD 13.2 billion in 2022 and is expected to reach USD 32.5 billion by 2031, growing with a CAGR of 12.30% during the forecast period 2026-2031.
The Global Cancer Biomarker Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Cancer Biomarker Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Cancer Indication
Both primary and secondary data sources have been used in the global Global Cancer Biomarker Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Global Cancer Biomarker Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Global Cancer Biomarker Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Cancer Indication
- Sarcoma*
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Breast Cancer
- PSA*
- HER-2
- EGFR
- KRAS
- Others
- OMICS Technologies*
- Cytogenetics
- Immunoassays
- Imaging Technologies
- Bioinformatics
- Hospitals*
- Academic and Cancer Research Institutes
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Global Cancer Biomarker Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Cancer Indication
3.2. Snippet by Biomarker Type
3.3. Snippet by Profiling Technology
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence of Cancer
4.1.1.2. Increase in Strategic Developments
4.1.2. Restraints
4.1.2.1. High Cost of Biomarkers
4.1.3. Opportunity
4.1.3.1. Development of Personalized Medicine
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY CANCER INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
7.1.2. Market Attractiveness Index, By Cancer Indication
7.2. Sarcoma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Colorectal Cancer
7.4. Cervical Cancer
7.5. Lung Cancer
7.6. Breast Cancer
8. BY BIOMARKER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. PSA*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. HER-2
8.4. EGFR
8.5. KRAS
8.6. Others
9. BY PROFILING TECHNOLOGY
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
9.1.2. Market Attractiveness Index, By Profiling Technology
9.2. OMICS Technologies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cytogenetics
9.4. Immunoassays
9.5. Imaging Technologies
9.6. Bioinformatics
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic and Cancer Research Institutes
10.4. Ambulatory Surgical Centers
10.5. Diagnostic Laboratories
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. F. Hoffmann-La Roche Ltd*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Thermo Fisher Scientific, Inc.
13.3. QIAGEN N.V.
13.4. Illumina, Inc.
13.5. Bio-Rad Laboratories, Inc.
13.6. Abbott Laboratories
13.7. bioM?rieux SA
13.8. Enzo Biochem, Inc.
13.9. Merck Millipore
13.10. Micron Technology(*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Cancer Indication
3.2. Snippet by Biomarker Type
3.3. Snippet by Profiling Technology
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence of Cancer
4.1.1.2. Increase in Strategic Developments
4.1.2. Restraints
4.1.2.1. High Cost of Biomarkers
4.1.3. Opportunity
4.1.3.1. Development of Personalized Medicine
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY CANCER INDICATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
7.1.2. Market Attractiveness Index, By Cancer Indication
7.2. Sarcoma*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Colorectal Cancer
7.4. Cervical Cancer
7.5. Lung Cancer
7.6. Breast Cancer
8. BY BIOMARKER TYPE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
8.1.2. Market Attractiveness Index, By Biomarker Type
8.2. PSA*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. HER-2
8.4. EGFR
8.5. KRAS
8.6. Others
9. BY PROFILING TECHNOLOGY
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
9.1.2. Market Attractiveness Index, By Profiling Technology
9.2. OMICS Technologies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cytogenetics
9.4. Immunoassays
9.5. Imaging Technologies
9.6. Bioinformatics
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic and Cancer Research Institutes
10.4. Ambulatory Surgical Centers
10.5. Diagnostic Laboratories
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Indication
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomarker Type
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Profiling Technology
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. F. Hoffmann-La Roche Ltd*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Thermo Fisher Scientific, Inc.
13.3. QIAGEN N.V.
13.4. Illumina, Inc.
13.5. Bio-Rad Laboratories, Inc.
13.6. Abbott Laboratories
13.7. bioM?rieux SA
13.8. Enzo Biochem, Inc.
13.9. Merck Millipore
13.10. Micron Technology(*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
